Celebrex and Bextra MDL Assigned to California
Last week the Judicial Panel on Multidistrict Litigation assigned all federal Celebrex and Bextra cases to the Northern District of California before the Honorable Charles R. Breyer. The MDL will handle all federal claims arising out of the use, marketing and sales of Celebrex and Bextra. Following in the footsteps of Vioxx, these other cox-2 inhibitors will be grouped together for resolution of pretrial issues and discovery.
Read the Transfer Order here.
Post A Comment / Question